Viking Therapeutics’ GLP-1 pill candidate shows promise in latest study
Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage biopharma announced Monday. In a study that tested the highest dosage of 100-mg, the drug — known as KV2735 — resulted in an average of 6.8% body weight reduction after 28 days compared to placebo.
Viking Therapeutics has announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.
Shares of Viking Therapeutics (NASDAQ: VKTX) fell on Monday, Nov. 4, despite some encouraging new data. Over the weekend, the ...
Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's ...
Viking Therapeutics highlights VK2735's promising weight loss data at ObesityWeek 2024, with up to 14.7% reduction and ...
Viking Therapeutics shares surge as VK2735 shows significant weight loss in early-stage study, with plans for a phase 2 ...
Viking Therapeutics (VKTX) surges on promising obesity drug results. Explore key price levels and analyst insights in this detailed analysis.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback